![1]()
News
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
September 25, 2020
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25.
News
Deaths sky high in hospitalized COVID patients with kidney injury
September 9, 2020
“We may be facing an epidemic of post–COVID-19 kidney disease and that, in turn, could mean much greater numbers of patients who require kidney dialysis and even transplants.”
![1]()
News
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
August 31, 2020
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
![1]()
News
Real-world data show SGLT2 inhibitors for diabetes triple DKA risk
July 29, 2020
The findings are based on the use of three different SGLT2 inhibitors in Canada and the United Kingdom.
![1]()
News
One-year mortality after dialysis initiation nearly double prior estimates
July 3, 2020
What is the 1-year mortality rate after dialysis initiation in patients older than age 65 years?
![1]()
News
Canagliflozin protects diabetic kidneys
July 1, 2020
Do sodium-glucose cotransporter 2 (SGLT2) medications protect at-risk kidneys in type 2 diabetics?
News
Where does dexamethasone fit in with diabetic ketoacidosis in COVID-19?
June 22, 2020
Author of new article discussing considerations around diabetic ketoacidosis in the setting of COVID-19 also speaks to the findings this week that dexamethasone could reduce deaths in the severely ill.
News
Large COVID-19 dataset: Kidney injury in >35% of those in hospital
May 20, 2020
The clearest risk factors for the development of AKI were “the need for ventilator support or vasopressor drug treatment.”
![1]()
News
Acute kidney injury in children hospitalized with diarrheal illness in the U.S.
April 29, 2020
Diarrheal illness is the fourth leading cause of death for children younger than 5 years and the fifth leading cause of years of life lost globally.
News
Dapagliflozin trial in CKD halted because of high efficacy
March 30, 2020
An independent data monitoring committee recommended stopping the trial.
